GLP-1 and nicotine combination therapy engages hypothalamic and mesolimbic pathways to reverse obesity
Cell Reports · 2023-05 · 42 (5) · 112466
DOI: 10.1016/j.celrep.2023.112466 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Reports, 2023-05. Verfasst von Sarah Falk und 17 weiteren Autor:innen. Beteiligte Einrichtung: Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Glucagon-Like Peptide 1, Liraglutide. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Københavns Universitet, Lundbeck Foundation, Novo Nordisk Fonden.
Abstract (Originalsprache)
Glucagon-like peptide-1 receptor (GLP-1R) agonists promote nicotine avoidance. Here, we show that the crosstalk between GLP-1 and nicotine extends beyond effects on nicotine self-administration and can be exploited pharmacologically to amplify the anti-obesity effects of both signals. Accordingly, combined treatment with nicotine and the GLP-1R agonist, liraglutide, inhibits food intake and increases energy expenditure to lower body weight in obese mice. Co-treatment with nicotine and liraglutide gives rise to neuronal activity in multiple brain regions, and we demonstrate that GLP-1R agonism increases excitability of hypothalamic proopiomelanocortin (POMC) neurons and dopaminergic neurons in the ventral tegmental area (VTA). Further, using a genetically encoded dopamine sensor, we reveal that liraglutide suppresses nicotine-induced dopamine release in the nucleus accumbens in freely behaving mice. These data support the pursuit of GLP-1R-based therapies for nicotine dependence and encourage further evaluation of combined treatment with GLP-1R agonists and nicotinic receptor agonists for weight loss.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
- Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; Department of Drug Design and Pharmacology, Faculty of Health and Medic…
- Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
- Department of Neuroscience, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
- Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; Department of Neuroscience, Faculty of Health and Medical Sciences, Uni…
- Gubra, Hørsholm, Denmark.
Förderung
- Københavns Universitet
- Lundbeck Foundation
- Novo Nordisk Fonden
Zitieren
APA
Falk, S., Petersen, J., Svendsen, C., Romero-Leguizamón, C. R., Jørgensen, S. H., Krauth, N., Ludwig, M. Q., Lundø, K., Roostalu, U., Skovbjerg, G., Nielsen, D. A. G., Ejdrup, A. L., Pers, T. H., Dmytriyeva, O., Hecksher-Sørensen, J., Gether, U., Kohlmeier, K. A., & Clemmensen, C. (2023). GLP-1 and nicotine combination therapy engages hypothalamic and mesolimbic pathways to reverse obesity. Cell Reports, 42(5), 112466. https://doi.org/10.1016/j.celrep.2023.112466
Vancouver
Falk S, Petersen J, Svendsen C, Romero-Leguizamón CR, Jørgensen SH, Krauth N, et al. GLP-1 and nicotine combination therapy engages hypothalamic and mesolimbic pathways to reverse obesity. Cell Reports. 2023;42(5):112466. doi:10.1016/j.celrep.2023.112466
BibTeX
@article{Falk2023,
author = {Falk, Sarah and Petersen, Jonas and Svendsen, Charlotte and Romero-Leguizamón, Cesar R and Jørgensen, Søren Heide and Krauth, Nathalie and Ludwig, Mette Q and Lundø, Kathrine and Roostalu, Urmas and Skovbjerg, Grethe and Nielsen, Duy Anh Gurskov and Ejdrup, Aske Lykke and Pers, Tune H and Dmytriyeva, Oksana and Hecksher-Sørensen, Jacob and Gether, Ulrik and Kohlmeier, Kristi A and Clemmensen, Christoffer},
title = {GLP-1 and nicotine combination therapy engages hypothalamic and mesolimbic pathways to reverse obesity},
journal = {Cell Reports},
year = {2023},
volume = {42},
number = {5},
pages = {112466},
doi = {10.1016/j.celrep.2023.112466}
}
EUVIMED